Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCRL2 | O00421 | 14/20 | 0.58 |
| ▸ | CCR2 | P41597 | 6/20 | 0.55 |
| ▸ | CCR5 | P51681 | 5/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5033619 | 1.00 | CCRL2 (0.58) | CCRL2CCR2CCR5CHRM2CHRM4 | |
| SCHEMBL5029600 | 0.89 | CCR2 (0.63) | CCRL2CCR2CCR5CHRM2CHRM4 | |
| SCHEMBL5029605 | 0.89 | CCR2 (0.63) | CCRL2CCR2CCR5CHRM2CHRM4 | |
| SCHEMBL5031962 | 0.88 | CCRL2 (0.55) | CCRL2 | |
| SCHEMBL5031959 | 0.88 | CCRL2 (0.55) | CCRL2 | |
| SCHEMBL5029582 | 0.87 | CCRL2 (0.61) | CCRL2CCR2CCR5CHRM2CHRM4 | |
| SCHEMBL5027181 | 0.87 | CCR2 (0.51) | CCR2CCR5KCNH2CYP2D6 | |
| SCHEMBL5027185 | 0.87 | CCR2 (0.51) | CCR2CCR5KCNH2CYP2D6 | |
| SCHEMBL5030415 | 0.82 | CCR2 (0.52) | CCRL2CCR2CCR5CHRM2CHRM4 | |
| SCHEMBL5030409 | 0.82 | CCR2 (0.52) | CCRL2CCR2CCR5CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7378409-B2 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-05-27 | — | — | US | disclosed |
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | BRISTOL-MYERS SQUIBB COMPANY | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054626-A1 | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity | CCL11, CCR1, CCR2 | CCRL2 15/4885CCR2 3/4885CCR5 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.